Biotech Firm ImmuneOnco Submitted Listing Application on the Main Board of HKEX
ImmuneOnco, focusing on developing new-generation tumor immunotherapeutic, will further accelerate the development of other promising drug candidates targeting checkpoints of innate and adaptive immunity.
Updated 32 mins ago
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM